Clinical Trial

Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated Glomerulonephritis

Name: Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated Glomerulonephritis — clinical trial record (NCT07746180)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study is an open-label, single-arm, exploratory study designed to evaluate the efficacy and safety of Obinutuzumab beta combined with a rapid-tapering glucocorticoid regimen in patients with new-onset ANCA-associated glomerulonephritis (AAGN).

Trial Details

NCT Number	NCT07746180
Lead Sponsor	Chinese PLA General Hospital
Conditions	ANCA-Associated Glomerulonephritis (AAGN), ANCA-Associated Vasculitis (AAV)
Enrollment	20 participants
Start Date	2026-07-31
Primary Completion	2028-10-30 (estimated)
Study Completion	2029-03-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-04